欧林生物
(688319)
| 流通市值：113.72亿 | | | 总市值：113.72亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 598,935,631.15 | 361,322,181.04 | 157,803,808.92 | 704,160,325.32 |
| 营业总成本 | 506,294,647.39 | 310,823,899.43 | 136,476,818.31 | 659,117,720.56 |
| 其他经营收益 | | | | |
| 营业利润 | 86,165,574.44 | 57,093,154.54 | 32,392,401.95 | 30,857,171.48 |
| 利润总额 | 54,125,013 | 26,184,409.94 | 32,422,385.42 | 31,893,209.89 |
| 净利润 | -6,808,775.94 | -32,879,690.92 | 27,197,714.68 | 21,898,737.19 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -6,808,775.94 | - | 27,197,714.68 | 21,898,737.19 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,063,289,562.97 | 1,075,290,027.48 | 998,755,242.25 | 996,333,512.94 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,059,179,365.23 | 1,024,425,704.49 | 1,021,156,465.74 | 1,026,736,270.08 |
| 资产总计 | 2,122,468,928.2 | 2,099,715,731.97 | 2,019,911,707.99 | 2,023,069,783.02 |
| 流动负债: | | | | |
| 流动负债合计 | 819,764,916.73 | 836,288,213.46 | 737,061,113.92 | 737,073,224.41 |
| 非流动负债: | | | | |
| 非流动负债合计 | 407,307,208.54 | 394,101,630.56 | 351,673,180.47 | 382,016,859.69 |
| 负债合计 | 1,227,072,125.27 | 1,230,389,844.02 | 1,088,734,294.39 | 1,119,090,084.1 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 895,396,802.93 | 869,325,887.95 | 930,868,035.65 | 903,678,718.78 |
| 股东权益合计 | 895,396,802.93 | 869,325,887.95 | 931,177,413.6 | 903,979,698.92 |
| 负债和股东权益合计 | 2,122,468,928.2 | 2,099,715,731.97 | 2,019,911,707.99 | 2,023,069,783.02 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 536,678,145.59 | 343,176,571.45 | 136,960,725.75 | 670,816,894.15 |
| 经营活动现金流出小计 | 591,131,564.48 | 413,577,497.93 | 162,385,314.26 | 565,323,116.79 |
| 经营活动产生的现金流量净额 | -54,453,418.89 | -70,400,926.48 | -25,424,588.51 | 105,493,777.36 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 135,224,646.79 | 135,125,136.99 | 135,125,136.99 | 200,525,572.57 |
| 投资活动现金流出小计 | 228,550,467.61 | 159,608,881.09 | 157,909,127.36 | 323,020,455.58 |
| 投资活动产生的现金流量净额 | -93,325,820.82 | -24,483,744.1 | -22,783,990.37 | -122,494,883.01 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 204,000,000 | 134,000,000 | 20,000,000 | 176,100,000 |
| 筹资活动现金流出小计 | 150,749,408.57 | 59,831,836.2 | 26,103,399.86 | 151,699,743.83 |
| 筹资活动产生的现金流量净额 | 53,250,591.43 | 74,168,163.8 | -6,103,399.86 | 24,400,256.17 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | -94,528,648.28 | -20,716,506.78 | -54,311,978.74 | 7,399,150.52 |
| 期末现金及现金等价物余额 | 130,647,333.25 | 204,459,474.75 | 170,864,002.79 | 225,175,981.53 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -20,716,506.78 | - | 7,399,150.52 |
最新报告期：2026-09-07| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中信建投 | 汤然,刘若飞,贺菊颖 | -0.01 | 0.23 | 0.32 | 2026-09-07 |